← Back to Clinical Trials
Recruiting NCT07417176

NCT07417176 Persistent COVID-19 Registry in Navarre.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07417176
Status Recruiting
Phase
Sponsor Fundacion Miguel Servet
Condition Long COVID Symptoms
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2021-01-04
Primary Completion 2026-03-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2021-01-04 with a primary completion date of 2026-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to deepen our understanding of long COVID by determining the prevalence of the main complications and medium- to long-term sequelae of COVID-19 in Navarre. Sociodemographic variables such as age, sex, ethnicity, smoking history, and comorbidities will be collected, as well as clinical and disease management variables such as persistent COVID-19 symptoms at 3 months, all with the aim of characterizing patients with long COVID. All patient data will be collected in a single visit.

Eligibility Criteria

Inclusion Criteria: * History of confirmed SARS-CoV-2 infection * Presentation of symptoms that have persisted for more than 3 months after SARS-CoV-2 infection * The patient reports any of the symptoms listed in the clinical assessment questionnaire or checklist. Exclusion Criteria: * The symptom(s) referred to already existed prior to acute SARS-CoV-2 infection.

Contact & Investigator

Central Contact

Ruth García Rey, SC

✉ ruth.garcia.rey@navarra.es

📞 +3484822163

Principal Investigator

Patricia Fanlo Mateo, MD, PhD

PRINCIPAL INVESTIGATOR

Hospital Universitario de Navarra. Pamplona. Spain

Frequently Asked Questions

Who can join the NCT07417176 clinical trial?

This trial is open to participants of all sexes, studying Long COVID Symptoms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07417176 currently recruiting?

Yes, NCT07417176 is actively recruiting participants. Contact the research team at ruth.garcia.rey@navarra.es for enrollment information.

Where is the NCT07417176 trial being conducted?

This trial is being conducted at Pamplona, Spain.

Who is sponsoring the NCT07417176 clinical trial?

NCT07417176 is sponsored by Fundacion Miguel Servet. The principal investigator is Patricia Fanlo Mateo, MD, PhD at Hospital Universitario de Navarra. Pamplona. Spain. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology